Lung cancer (LC) represents the most common solid tumor in survivors of 
Hodgkin's disease (HD), and the assessment of the mutational status of oncogenic 
driver mutations in LC is now standard. We compiled clinical and mutation data 
(EGFR, KRAS, and ALK) from the medical records of patients with LC and a remote 
history of HD. 13 cases of LC following HD were seen, including seven with 
mutational data. Two had EGFR mutations, none had KRAS mutations or ALK 
translocations. Our conclusions are limited by the small sample size, however 
this report reinforces the need to identify driver mutations in lung cancers.